Archive for September, 2009

Academic Half Day- Project Presentation

Code Black= bomb

Code Red= fire from bomb

Code Yellow= missing patient who set off the bomb

We had our project presentation at SPH. I got many good feedback that I plan on implementing for my project. Some of these suggestions include:

  • classifying adverse events into either severe or minor events
  • defining shock
  • define DKA and HHS diagosis

Other things that I’ve learned at the AHD:

  • cohort study –> look at % of pt receiving drug and go forward to see outcomes
  • case study–> look at outcome and go back to see % of pt receiving drug

Leave a Comment

Medicine- Day 16

Beth is not feeling well today. Get better soon Beth!!!!

Interstitial Nephritis

Symptoms

▪                Often initially asymptomatic

▪                Arthralgia

▪                Hematuria (gross hematuria is rare)

▪                Nausea and vomiting

▪                Malaise

▪                Anorexia

Signs

▪                Fever

▪                Rash

▪                Oliguria

Patients with drug-induced AIN may have signs and symptoms of an allergic process, e.g. rash, fever, eosinophilia (although these are absent in NSAID-induced AIN)

▪                Urinalysis typically reveals moderate to minimal proteinuria (except in nonsteroidal anti-inflammatory drug (NSAID)-induced acute interstitial nephritis (AIN), in which proteinuria may reach nephrotic range), sterile pyuria, absence of red blood cell casts, and frequently eosinophiluria, but none of these findings are pathognomonic

▪                50-70% of cases resolve on withdrawal of the causative agent within 7-10 days, and most (70%) make a good recovery

▪                Some patients (20-30%) have residual renal impairment, and may progress to end-stage renal failure

▪                Characteristically, patients present with a sudden deterioration in renal function (often with oliguria) several days to weeks after the introduction of a new medication

▪                Patients with drug-induced acute interstitial nephritis (AIN) may have signs and symptoms of an allergic process, e.g. rash, fever, eosinophilia, but these may be absent in more than half of all cases

Common causes

AIN may be drug-induced (85% of cases). Common drugs associated with AIN include:

▪                NSAIDs (including COX-2 inhibitors), proton pump inhibitors, ciprofloxacin, 5-aminosalicylates, penicillin, methicillin, rifampin, cephalosporins, trimethoprimsulfamethoxazole, thiazides, furosemide, triamterene, allopurinol, phenytoin, captopril, and cimetidine

AIN may be infection-induced. Infections associated with AIN include:

▪                Streptococcus, Legionella, Corynebacterium diphtheriae, Yersinia, Salmonella, HIV, Epstein-Barr virus (EBV), cytomegalovirus (CMV), Rickettsia, and Mycobacterium tuberculosis

Summary of Therapies

All treatments are given under the supervision of a nephrologist:

▪                Withdrawal of any offending medication: in 50-70% of patients in which the offending medication is withdrawn, resolution of the condition may begin within 7-10 days

▪                Corticosteroids: a trial of a corticosteroid, such as prednisone, should be considered if there is no improvement within 7-10 days after withdrawal of a medication thought to be responsible. Prior to initiation of corticosteroid therapy, a renal biopsy must be performed to confirm the diagnosis of acute interstitial nephritis (AIN) and to rule out the presence of significant degrees of interstitial fibrosis. If present, fibrosis contraindicates the use of immunosuppressive medications such as corticosteroids and cyclophosphamide, because these agents are ineffective in the presence of fibrosis, and they have serious adverse effects. Corticosteroids should be avoided in patients with active infection. Patients treated with corticosteroids should notice some improvement within 1-2 weeks, in which case the medication should be continued for 8-12 weeks with gradual tapering of the dose. If no improvement is noted in the first 2 weeks, the addition of cyclophosphamide might be considered upon recommendation and supervision by the consulting nephrologist

Prednisone Oral:

▪                1mg/kg/day given in four divided doses

▪                Alternate regimen: 2mg/kg/day given every other day

▪                Treatment course: 8-12 weeks

▪                Cyclophosphamide: a second-line treatment; may be superimposed on the corticosteroid regimen (if renal biopsy shows little or no interstitial fibrosis) for a total treatment period not to exceed 2-3 months. If no improvement is seen, the medications should be stopped after 6 weeks

Differential Dx

Tubular necrosis:

Patients present with acute renal failure of sudden onset, and may develop oliguria, in a similar fashion to patients with AIN. However, patients with ATN usually have a history of a severe renal insult, such as prolonged hypovolemia or sepsis. On urinary microscopy eosinophiluria is not seen.

Features

▪                History of renal insult

▪                Many patients develop oliguria

▪                Urine sediment contains muddy brown casts and tubular epithelial cells

▪       intrinsic renal failure is most commonly associated with acute tubular necrosis (ATN) following severe systemic insult, e.g. surgery, trauma, burns, hypotension, sepsis

Symptoms

▪                May rarely be asymptomatic

▪                Lethargy, weakness

▪                Anorexia

▪                Nausea and vomiting

▪                General malaise

▪                Muscle cramps

▪                Decreased consciousness

Coma

Delirium or confusion

Drowsy, lethargic, hard to arouse

▪                Decreased urine output or no urine output

▪                General swelling, fluid retention

Nausea, vomiting

Signs

▪                Skin pallor

▪                Ecchymoses

▪                Peripheral edema

▪                Tachypnea

▪                Tachycardia

▪                Confusion

▪                Seizures

▪                Oliguria or anuria

▪                Pulmonary rales secondary to volume overload

▪                Arrhythmias secondary to hyperkalemia and severe acidosis

▪                Asterixis or flapping tremors

▪       Uremic fetor

Treatment

▪       aggressive fluid resuscitation to restore intravascular volume may reduce incidence of acute tubular necrosis (ATN)

▪       Judicious use of a diuretic such as furosemide often converts an anuric or oliguric patient to a nonoliguric patient, and makes the management of the patient easier; however, the prognosis of the acute renal failure does not change

▪       Dietary modification may be necessary in ATN to provide adequate calories while minimizing accumulation of toxins by moderate short-term protein restriction. Prolonged protein restriction is inadvisable and may delay recovery

Leave a Comment

Sepsis- FMI

Criteria for SIRS were established in 1992 as part of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.[1] The conference concluded that the manifestations of SIRS include, but are not limited to:

SIRS can be diagnosed when two or more of these criteria are present

Leave a Comment

Medicine- Day 15

Mondays are always busy…

FMI:

Prostatism:Difficulty urinating caused by benign enlargement of the prostate gland is called prostatism. Such enlargement is also called Benign Prostatic Hyperplasia or BPH. BPH is the most common benign tumor in men and is responsible for some urinary symptoms in most men over the age of 50. It is thought that between 20 to 30 percent of men will need medical or surgical treatment of BPH before they reach age 80.

Tx: alpha 1 blockers ( ie. terazosin, tamsulosin) or 5 alpha reductase inhibitor ( dutasteride)

List of drugs that causes thrombocytopenia
(anti-neoplastic drugs are not included)

  • Quinine/Quinidine group
    • Quinine
    • Quinidine
  • Heparin
    • Regular unfractionated heparin
    • Low molecular weight heparin
  • Gold salts
  • Antimicrobials
    • Antimony containing drugs
      • Stibophen
      • Sodium stibogluconate
    • Cephalosporins
      • Cephamandazole
      • Cefotetan
      • Ceftazidime
      • Cephalothin
    • Ciprofloxacin
    • Clarithromycin
    • Fluconazole
    • Fusidic
    • acid

    • Gentamicin
    • Nilidixic acid
    • Penicillins
      • Ampicillin
      • Apalcillin
      • Methicillin
      • Meziocillin
      • Penicillin
      • Piperacillin
    • Pentamidine
    • Rifampin
    • Sulpha group
      • Sulfamethoxazole
      • Sulfamethoxypyridazine
      • Sulfisoxazole
    • Suramin
    • Vancomycin
  • Anti-inflammatory drugs
    • Acetaminophen
    • Salicylates
      • Aspiring
      • Diflunisal
      • Sodium amiosalicylate
      • Sulfasalazine
    • Diclofenac
    • Fenoprofen
    • Ibuprofen
    • Indomethacin
    • Meclofenamate
    • Mefanamic acid
    • Naproxen
    • Oxyphebutazone
    • Phenylbutazone
    • Piroxicam
    • Sulindac
    • Tolmetin
  • Cardiac medications and diuretics
    • Digoxin
    • Digitoxin
    • Amiodarone
    • Procainamide
    • Alprenolol
    • Oxprenolol
    • Captopril
    • Diazoxide
    • Alpha-methyldopa
    • Acetazolamide
    • Chlorothiazide
    • Chlorthalidone
    • Furosemide
    • Hydrochlorothiazide
    • Sprinolactone
  • Benzodiazepines
    • Diazepam
  • Anti-epileptic drugs
    • Carbamazepine
    • Phenytoin
    • Valproic acid

    H2-antagonists

    • Cimetidine
    • Ranitidine
  • Sulfonylurea drugs
    • Chlorpropamid
    • Glibenclamide
  • Iodinated contrast agents
  • Retinoids
    • Isotretinoin
    • Etretinate
  • Anti-histamines
    • Antazoline
    • Chlorpheniramine
  • Illicite drugs
    • Cocaine
    • Heroin
    • Qunine containment
  • Antidepressants
    • Amitriptyline
    • Desipramine
    • Doxepin
    • Imipramine
    • Mianserine
  • Miscellaneous drugs
    • Tamoxifen
    • Actinomycin-D
    • Aminoglutethimide
    • Danazole
    • Desferrioxamine
    • Levamizole
    • Lidocaine
    • Morphine
    • Papaverine
    • Ticlopidine

Table 1
Table 1. Drugs Commonly Implicated as Triggers of Drug-Induced Thrombocytopenia.

Leave a Comment

Medicine- Day 14

PROJECT approved by ethics!!! YAY!

I am alittle disappointed by the GP’s response to one of my recommedations today. The patient has been on flagyl for 12 days after being found +ve for c diff. Her sx had improved throughout treatment. After the patient was taken off therapy, her diarrhea episodes began to increase again. I phoned the doctor asking to resume the metronidazole therapy again, but the GP wants to wait for culture results for the toxin. In the meantime, the patient is experiencing approx 6 ep of loose diarrhea per day. I think that I am more disappointed that I was not assertive enough on behalf of the patient.

Didactics on Alcoholic Cirrhosis:

  • alcoholic cirrhosis has 3 components: hyperlasia of firbrous connective tissue, hepatitis with injury from inflammation and steatosis from abnormal retention of lipids
  • the Child- Pugh Classification is used to determine severity; components of classification: bilirubin, albumin, ascites and encephalitis; 80% survival rate in pt with 2 points; 30% survival rate in patients with 3 points
  • portal hypertension complications: ascites, hepatio-renal syndrome, esophageal varices, encephalopathy
  • AST/ALT: enzyme released if cell is injured
  • spleen and GI lead to portal vein
  • Increased risk of hepatic hypertension: hepatotoxin (tylenol), women, viral hepatitis, genetics, liver diseases
  • NADH–> NAD; hydrolysis process lead to increase fatty acide and TG; fatty infiltration as a result
  • portal hypertension is define has great than 12 mmHg; normal pressure is 5-10mmHg; this is not measured in practice
  • hepatitis is reversible, cirrhosis is irreversible
  • sx of alcoholic cirrhosis: spider angiomas is usually across face or nose–> broken capillaries–> not reversible–> need laser therapy; jaundice eyes; anorexia; abd discomfort; weakness/ umbilical vein dilateion ( aka caput medusa)
  • Dx for alcoholic cirrhosis: hold hand against tummy and tap on the stomach with the other hand; should see a wave of fluid–> differentiates from mass/preg
  • portal HTN tx: stop alcohol, replenish nutrition
  • salt restriction of 20 mEq/L if decrease water and Na less than 130mEq/L
  • increased conjugated bilirubin–> jaundice
  • often see increase INR because increase PT with decrease clotting factor production
  • blood urea nitrogen–> liver makes urea–> therefore, decrease BUn–> nitrogen decrease b/c poor mutritional status
  • cachalsia: lose muscle mass, then, poor protein intake, liver stores glycogen–> liver can’t store glucose, so breakdown muscle
  • increase nitrogen contribute to encephalopathy
  • normal protein diet (35-50g /day) is recommended for alcoholic cirrhosis pt –> or else they will get encephalopathy
  • decrease albumin in blood–> h2o push out of vein b/c low albumin and increase pressure–> fluid in blood flow to peritoneal
  • safe wt lost is 0.5-2 kg/day
  • Ascites tx: diuretic ( spironolactone 100-300 mg/day) or surgery- paracentesis ( needle in, get fluid out)–> diuresis slowly  to re-equilibrate with vascular volume
  • following paracentesis–> there is a period of impaired circulatory function which manifests as a reduction in CO and worsening renal function for 24-48 hours post–> give IV 50 mL of 25% alubmin soln per litre of ascites removed
  • esophageal varices–> vessels dilated ( vein pops out)
  • tx esophageal varices with: (1) vit K 10 mg IV/PO/SC; IV vit K can cause anahylactic reaction if not diluted or infused quickly (2) vasopressin : not specific, constricts blood vessel (3) octreotide bolus or somastatin( normally in body) infusion (3) NG tube to drain blood in stomach –> give fluids (4)inj 0.5 to 5 mL of sclerosing agent (5) band placed around mucosa and submosa of esophageal
  • Prevention of esophageal varices: beta blockers ( non selective) because they reduce hepatic blood flow and porta pressure; no decrease in mortality; have adrenergic effect in mesenteric arterioles which decreases portal blood circulation  (i.e. propanolol and nadolol)
  • primary prevention: 25-40% of ppl get cirrhosis that bleed
  • encephalopathy: protein in blood–> stomach bleed–> protein changed to ammonia in GI by bacteria–> absorb in system–> go to CNS–> form glutamine–> encephalopathy
  • encephalopathy–> stop CNS depressant ( ie. ciwa protocol–> ex. bdz)
  • tx of encephalopathy: (1) laculose 30-45 mL tid –> changes ammonia to ammonium, which is less readily aborbed–> increase gi transit time; se: gaseous distention, flatuence, belching; dose to have loose stool, not diarrhea (2) neomycin is not available in Canada; usually metronidazole –> interact with alcohol to cause flushing reaction and metallic taste (3) zinc–> encephalopathy can be cause by zinc deficiency
  • SPONTANEOUS BACTERIAL PERITONITIS (SBS): caused by e coli, K pneumonia and s pneumona; tx with 3rd gen ceph, FQ, beta-lactam + lactamse inhibitor
  • SBS prophylaxis after 2nd ep, usually with norfloxacin 400 mg daily, TMP-SMX or amox/clav

Leave a Comment

Medicine- Day 13

Procedure Log: Vanco dosing

Today, we received a pre-vanco level back. It was taken prior to 4th dose. The patient had received the 3 prior dose in a timely manner; however, the dose was taken 30 min later than suggested. As a result, the trough may be lower than expected. The target level for our patient was between 15 to 20. The level returned as 3. Based on the patient’s weight, age and creatinine clearance, it was determined that the patient is receiving an insufficient amount of vancomycin. I suggested that the patient’s dose be changed to 1250 mg q 8 hours and to have his vanco level remeasured along with serum creatinine and BUN at the same time.

After conversing with the physician in regards to some of the patient’s drug related problems, the physician agreed to the recommendations made. I then transcribed the new PPI and vanco order onto the medication profile. It is very convenient to have a physician who is easily accessible on the ward. What I found to be more beneficial is to hear what the GP has to say about how they went about deciding on the patient’s therapy. It is interesting and useful to hear their rationale.

Lesson of the day:
The patient is ultimately responsible for their own health. It is our role to empower them to do so.

FMI:

  • max physiological creatinine clearance is 120ml/min
  • CHOP-R is a chemo protocol: cyclophosphamide, vincristine, doxorubicin + ritaximab
  • Useful link: http://www.bccancer.bc.ca
    – BC Cancer Agency
    – go to: health professional information OR search

Leave a Comment

Medicine- Day 12

Today we had an academic half day session on pneumonia, presented by Glen Brown.

I thought that the case based presentation was very effective to bringing us through the thought process for pneumonia management. The interactive portion allowed many opportunities for us to speak out and engage in the discussion.

FMI:

  • SPACE: Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter–> gram negative requiring extended spectrum
  • ESBL- enzyme  hydrolyze beta lactamase–> DOC: carbapeneum, avoid using carbapenem in other cases when possible
  • ESBL=ESBLs are capable of efficiently hydrolyzing penicillins, narrow spectrum cephalosporins, many extended-spectrum cephalosporins, the oxyimino group containing cephalosporins (cefotaxime, ceftazidime), and monobactams (aztreonam).
  • linezolid: bone marrow suppression
  • 2 agents that is active against one organism is not more effective than 1 agent that is active ( not synergistic)
  • sputum gram stain results can come back as early as 2 hours
  • sputum cultures can take 48 hours to get the results of
  • CURB-65 ( confusion, uremic: CrCl, RR greater than 30, SBP less than 90, DBP less than 60, age 65 or older)
  • top 4 org in order of prevalence: strep pneumo, moroxella catarrlis, atypical- mycoplasma/clamidyia, h. influ
  • moxi: broad spectrum ; work for all four org
  • azithro: increase resistance to s. pneumo; work for all four org
  • clarithro: many more drug interactions than azithro, BID dosing compare to azithro; better pseudomonas coverage
  • amox/clav: doesn’t cover atypicals, cover all other org
  • cefuroxime: doesn’t cover atypicals, cover all other org
  • cefuroxime + clarithro–> fill in gap of non-atypical coverage that cefuroxime misses
  • doxcycline: doesn’t cover atypicals
  • IV vs oral: n/v, admitting pt?, drug bioavailability, GI absorption?
  • in hospital doesn’t always require IV
  • if sensitive to Pen G–> can switch if hospitalized–> narrow spectrum used when ever possible
  • duration: once patient is afebrile for at least 48 hours and stable, WBC not always normal, but should be decreasing// no define number of days–> depends on how the patient responds
  • chest x ray will take approx 6 weeks to clear
  • severity of pneumonia affects: antibiotic specturm, antibiotic dose–> NOT duration
  • single dose of antibiotic pre/post op doesn’t count as a risk factor
  • 8 day therapy is just as good as 14 days
  • if pt has MRSA–> don’t tx unless pathogen is identified UNLESS they are high risk downtown east side pt
  • aspiration –> antibiotic needed if pt has altered GI motility or respiratory problem–> sputum should be cultured

Pack year is a term used to describe the number of cigarettes a person has smoked over time. One pack year is defined as 20 manufactured cigarettes (one pack) smoked per day for one year.

Example:

I smoked 1 1/2 packs per day for 26 years, which equals 39 pack years:

    1 pack per day x 26 years = 26 pack years
    1/2 pack per day x 26 years = 13 pack years
    26 pack years + 13 pack years = 39 pack years

Leave a Comment

Medicine- Day 11

Today, I lead a journal club discussion on the use of dabigatran vs warfarin in afib patients at risk of experiencing a stroke. My journal CONSORT assessment is available at my e-portfolio for viewing. There was a good discussion that happened after the paper presented. Some interesting questions were brought up that lead to interesting ideas.

Below is the CONSORT assessment on the trial assessed:
Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Didactics on DVT/PE:

  • DVT- virchow’s triad : (1) abnormalities of blood flow ( afib, obestity, bed rest, tumor), (2) abnormalities of clotting ( estrogen, preg, malignancy, thrombocytosis- platelet only, myloproliferative disorder – increased WBC and others) (3) abnormaliities of surfaces in contact with blood ( vasuclar injury, trauma)
  • for temporary DVT risk that can be resolved: bridging warfarin therapy can last 3 to 6 months
  • heparin tx for DVT: (1) 1 mg/kg BID enoxaparin or 1.5 mg /kg daily enoxaparin  (2) 175 units/kg daily for tinazparin (3) dalteparin : mostly for prophlaxis and surgery
  • (1) enoxaparin: more cardiac (2) tinzaparin : least renaly affected (3) dalteparin: mostly prophylaxis & surgery
  • LMWH: antiXa: antiIIa (2:1- 4:1); no aPTT monitoring, sc only; longer action–> pk stable- less binding; reversible
  • UFH: iv or sc ; irreversible; half life: 30 min to 2 1/2 hour ( short)
  • aPTT monitoring : q6 h, then daily when PTT stable
  • LMWH monitoring: anti-Xa
  • UFH switch to LMWH–> wait 12 hour ( based on half life)
  • no IM heparin–> cause hemotoma ( bruising)
  • heparin: ( large dose) affect Xa & IIa directly; ( small dose) affect Xa, indirectly inhibit IIa
  • DVT Prevention: (1) enoxaparin 30 mg BID or 40 mg daily (2) dalteparin 2500-5000 daily for surgery (3) 15 units/ g tinzaparin
  • venography: use contrast dye–> anaphylactic rx sometimes
  • HIT type 1: happens in 1st several days; moniroting –> don’t D/C  heparin
  • HIT type 2: happens between day 5 to 14–> d/c heparin ; don’t switch to LMWH
  • PE: Dx by VQ scan–> breath in –> check where blood perfuses to –> X ray to see if blood stops somewhere–? ventolation perfusion
  • PE: tx in hospital, not for outpatient therapy
  • vit K: take orally, given quickly–> anaphylactic rxn ( SOB, flushing)
  • INR more than 5, no bleed: skip dose
  • INR 5-9 , no bleed:  vit K 0.5- 2.5 mg orally
  • INR more than 9, no bleed: vit K 5-10 mg orally
  • DIC (Disseminated Intravascular Coagulopathy)–> clot & bleed at the same time; trigger: infection/malignancy; increase INR; increase aPTT; decrease pH; Clot in microvascular area ( brain, kidney, etc); don’t tx with anticoagulant; tx cause, fluid replacement, sx management; controversy on the use of heparin and fibrinolytic for management

FMI:

  • topiramate = aka the stupid drug
  • potassium: KCl elixir and Slow K ( 8mmol KCl) are available at the hospital
  • K-Dur  ( 20 mmol KCl) is not available at the hospital

CSHP Clinical Symposium

It has been a few years since my last CSHP clinical symposium. From what I remember from my last encounter, the material flew right over my head. It was very different this time. I felt that I understood the material and was eager to implement it in real practice.

  • ALLHAT: 1/3 black patients; 7 years old trial
  • BB: usually not 1st line in HTN management, no mortality benefit
  • ACCOMPLISH- 11,000 pt at high risk for HTN; CCB outperformed thiazides ( more peripheral edema in CCB; more hypotension in thiazide group; no difference in adverse events); 18% pt had less than 60ml/min GFR~ impaired diuretic efficacy; HCT inferior in bp effect in 24 hr post therapy; chlorthalidone ( half life : 12 hours) –> longer half life than HCTZ; chlorthalidone is twice as potent as HCTZ and they are non-interchangeable
  • risk factors for thiazide induced hyponatremia: lean women, elderly
  • controlled hypokalemia doesn’t correlate with controlled hyponatremia
  • low salt diet may be more effective than initiating therapy? sustained difference?
  • Aliskiren- direct renin inhibitor
  • Olmesartan–> most potent ARB
  • Predialysis solution may interfere with home glucose monitoring–> give false high reading
  • intermetant IP–> concentration dependent antibiotic curve
  • continuous IP–> time dependent antbiotics
  • COPD: nicotine replacement has best cessation rate for COPD smokers
  • inhaled anticholingerics doesn’t increase all cause morality ( meta-analysis: JAMA 2008)

Leave a Comment

Medicine- Day 10

Patients come and go so quickly that I hardly have the time to miss them before start taking on a new patient.

I did two warfarin discharge counsellings today. One was for a pt with DVT and another was for a pt with a PE. After my first patient, I realize that I should have a more consistent patient counselling format. This will ensure that I not miss any potential issues. It is also helpful to make the discussion relevant to the patient (ie. how much alcohol do you drink? do you play hockey? what time do you have breakfast?etc.)

COPD Didactics:

  • environmental factors: coal plants, espasis ( old insulation), wood smoke
  • complicaton: right sided heart failure ( cor pulmonale)
  • co-morbidities related to medication therapy: glaucoma , osteoporosis ( steriods)
  • dx: spirometer–> used in pt with sx….post bronchodilator less than 0.7 for FEV1/FVC
  • asthma : not related to sputum production, reversible, episodic, allergy related, onset younger age, doe not progress
  • corticosteroid correlate to increase risk of pneumonia
  • TORCH: surrogate marker FEV1 favors steriod, 10% of COPD can be managed with inhaled corticosteriods
  • neb: salbutamol, budesonide, ipratropiu<— can be given together
  • start antibiotic if pt is showing systemic infection ( febrile, WBC increase)
  • severe acute COPD exacerbation is related to gram negative bacterias
  • acute COPD exacerbation: H. influ, M. Catarrhalis, S. pneumo
  • abx use:

– simple: amox, doxy, septra, 2nd or 3rd gen ceph, extended spectrum macrolid

– severe: FQ, beta lactam / beta lactamse inhibitor

Leave a Comment

Medicine- Day 9

half way through the medicine rotation.

I am sad to see it go by so quickly. Beth and I did a midpt evaluation for the rotation and these are some things that I should continue to work on:
– communication
– basic therapeutics
– putting learnt material into “actual” patient scenarios

FMI:

  • UTI prophylaxis if the patient experiences 3 or more episodes per year
  • UTI prophylaxis: septra 1 ss tab daily OR septra 1 ss 3x weekly
  • hyoscine  or scoplamine: used to decrease secretion
  • Corrected calcium= measured calcium + 0.02 ( 40- alb)
  • calcium increase often related to cancer
  • B.A.D.= bipolar affective disorder

Leave a Comment

Older Posts »